Navigation Links
Aeras and China National Biotech Group Sign Memorandum of Understanding for TB Vaccine R&D Collaboration
Date:7/25/2011

ROCKVILLE, Md. and BEIJING, July 26, 2011 /PRNewswire-USNewswire/ -- Aeras and the China National Biotech Group (CNBG) today announced the signing of a memorandum of understanding for the organizations to pursue opportunities to jointly develop tuberculosis (TB) vaccines in China and potentially other parts of the world.

The partnership is intended to leverage both organizations' capabilities to support the development of TB vaccines.  TB is a major public health priority in China, where there are more than one million new TB cases every year.  The scope of potential activities will cover the full spectrum of product development, including pre-clinical development, process development and manufacturing, and clinical development in TB and potentially other disease areas.  Details of the specific activities and areas of focus of the collaboration will be set forth in a future definitive agreement.

"Aeras is excited to expand our relationship with CNBG," said Jim Connolly, President & Chief Executive Officer of Aeras. "The synergy created by bringing together CNBG's considerable infrastructure and manufacturing expertise with Aeras' promising TB vaccine pipeline, as well as our clinical and technical expertise, will significantly enhance the likelihood of a new TB vaccine being developed quickly and efficiently."

"At CNBG, we recognize the urgent need to combat tuberculosis and other infectious diseases in both China and around the world," said Xiaoming Yang, President of CNBG.  "This new collaboration will bring more opportunities to both organizations in pursuing greater innovation and building increased technical capacity for vaccine development."

The global TB epidemic is responsible for the deaths of 1.7 million people annually.  Co-infection with HIV/AIDS and the spread of drug-resistant forms of TB make it difficult to diagnose and treat, especially in poor and marginalized communities.  New tools to prevent TB, including vaccines, are urgently needed.

About Aeras

Aeras (www.aeras.org) is a non-profit product development organization dedicated to the development of effective TB vaccines and biologics to prevent TB across all age groups in an affordable and sustainable manner.  Aeras utilizes its broad capabilities and technologies in collaboration with numerous partners and stakeholders to support the development of vaccines and other biopharmaceuticals to address TB and other significant public health needs of underserved populations.  Aeras has invented or supported the development of six TB vaccine candidates to date, five of which are currently undergoing Phase I and Phase II clinical testing in Africa, Asia and North America.  Aeras receives funding from private foundations and governments.  Aeras is based in Rockville, Maryland, USA – where it operates a state-of-the-art manufacturing and laboratory facility – and Cape Town, South Africa.

About CNBG

CNBG (www.cnbg.com.cn) is a state-owned enterprise belonging to China's National Pharmaceutical Corporation (Sinopharm).  CNBG has 11 subsidiaries and is the largest biotech corporation in China engaged in the research and development, manufacturing and marketing of biological products. CNBG manufactures more than 200 kinds of biological products (with approximately 100 GMP product lines) for prophylactic, therapeutic and diagnostic use, including all the vaccines in China's EPI programme, and maintains an 80% share of the public sector in China. In 2010, the annual output of CNBG reached 730 million doses, and it maintains one of the broadest portfolios of vaccine products in the world.


'/>"/>
SOURCE Aeras
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Aeras, Crucell and South African Tuberculosis Vaccine Initiative Announce Encouraging Preliminary Results of Tuberculosis Vaccine Clinical Trial in South Africa
2. Aeras Global TB Vaccine Foundation Announces Appointment of Accomplished Pharmaceutical Executive as President and CEO
3. HUYA Bioscience Intl Announces Clinical Trial Milestones in China for Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile
4. HUYA Bioscience Intl Announces World-Class Clinical Advisory Team for New Anti-Arrhythmic Compound Sourced From China
5. HUYA Bioscience Intl Announces First Pre-IND Outcome for a Development Stage Compound Sourced From China - HBI-8000, Promising New Cancer Compound
6. HUYA Bioscience Intl Announces Pre-IND Outcome for HBI-3000 - Promising Anti-Arrhythmia Compound Sourced From China
7. China Sky One Medical, Inc. Announces 26 New Drugs in Clinical Trials
8. RHEI Pharmaceuticals Announces the Initiation of the Final Clinical Study for Approval of Tibozole in China
9. Varian Medical Systems to Exhibit Cancer Treatment and X-ray Imaging Technologies at China Med Exhibition
10. China Sky One Medical, Inc. Achieves Significant Breakthrough in Research for Sudden Cardiac Death (SCD) Early Examination Kit
11. China Animal Welfare Law Under Review While 36,000 Dogs Culled
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... -- ResMed (NYSE: RMD ), BMC ( Beijing, ... ) today announced they have agreed on a global settlement ... permitted to sell their existing products in exchange for royalty payments ... 3B to close the Florida litigation between ... liability or wrongdoing by any party. The five-year ...
(Date:1/21/2017)... Research and Markets has announced the addition of the ... Of Administration, End User - Forecast to 2025" report to ... The ... CAGR of around 7.8% over the next decade to reach approximately ... the global markets for Advanced Drug Delivery across all the given ...
(Date:1/20/2017)... , Jan. 20, 2017  Ethicon Endo-Surgery, ... Megadyne Medical Products, Inc., a privately held ... markets electrosurgical tools used in operating rooms ... of Ethicon,s* advanced energy devices with Megadyne,s ... major step forward in Ethicon,s goal to ...
Breaking Medicine Technology:
(Date:1/23/2017)... ... January 23, 2017 , ... Old School Labs™, makers of the wildly ... Physique bodybuilder Breon Ansley to its growing team of brand ambassadors. The Olympia top ... and in less than a year was able to turn professional, participating in the ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... resources at seafoodnutrition.org/programs and seafoodnutrition.org/resources to assist in teaching communities and individuals ... have been developed for use by nutrition educators and influencers within the ...
(Date:1/22/2017)... Raton, FL (PRWEB) , ... January 22, 2017 , ... ... to customers across the world, recently met with big-name retail buyers at the January ... scientific evidence of efficacy and uses the utmost safety standards in all of its ...
(Date:1/21/2017)... , ... January 21, 2017 , ... "ProDOF is the perfect set of tools for ... another subject in a scene," said Christina Austin - CEO of Pixel Film Studios. ... Easily create the illusion of a DSLR racking focus from one area into the ...
(Date:1/21/2017)... ... January 21, 2017 , ... ... medical office in Petaluma, located at 167 Lynch Creek Way. The Petaluma office ... SRO sports medicine and rehabilitation services and on-site x-ray services. Two multi-specialist ...
Breaking Medicine News(10 mins):